Company Overview

SAB Biotherapeutics, Inc. (SABS) is a U.S.-based clinical-stage biopharmaceutical company focused on the development of human polyclonal antibody therapies for infectious diseases and immunological conditions. The company operates within the biotechnology and biopharmaceutical industries, with a specialization in antibody discovery and manufacturing using a proprietary transchromosomic bovine platform that produces fully human antibodies at scale.

The company’s primary value proposition centers on its ability to rapidly generate broadly neutralizing, fully human polyclonal antibodies that may offer advantages over monoclonal antibodies in targeting mutating pathogens. SAB Biotherapeutics was founded in 2014 and became a publicly traded company in 2021 through a merger with Big Cypress Acquisition Corp., a special purpose acquisition company. Since inception, the company has remained focused on research and development and has not generated material commercial revenue.

Business Operations

SAB Biotherapeutics operates as a single, integrated biopharmaceutical business focused on research, development, and early-stage clinical testing of antibody-based therapeutics. Its core programs target infectious diseases such as influenza and emerging viral threats, leveraging its proprietary Tc Bovine® technology platform to generate fully human polyclonal immunoglobulins. Revenue to date has primarily consisted of grant and contract funding rather than product sales.

Operations are primarily domestic, with research, development, and manufacturing activities centered in the United States. The company controls specialized biological assets, including genetically engineered cattle capable of producing human antibodies, and maintains internal capabilities for antibody purification and preclinical development. The company has collaborated with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA), for the funding and advancement of certain infectious disease programs. Information on additional subsidiaries or joint ventures is limited; data inconclusive based on available public sources.

Strategic Position & Investments

Strategically, SAB Biotherapeutics is focused on advancing its pipeline through clinical development while expanding potential applications of its polyclonal antibody platform. Key development programs have included candidates targeting influenza and other viral pathogens, with an emphasis on pandemic preparedness and biodefense. The company’s strategy prioritizes non-dilutive funding through government partnerships and selective clinical advancement rather than large-scale commercial infrastructure buildout.

The company has made significant long-term investments in its proprietary production platform and manufacturing infrastructure rather than pursuing multiple acquisitions. No major corporate acquisitions have been publicly confirmed beyond the SPAC transaction that resulted in its public listing. Emerging areas of interest include broader infectious disease applications and immunological disorders, though the scope and timing of expansion beyond infectious diseases remain subject to ongoing clinical results and funding availability.

Geographic Footprint

SAB Biotherapeutics’ operations are primarily concentrated in North America, with headquarters in South Dakota, United States. Its manufacturing and research facilities are located domestically, supporting its focus on U.S.-based government partnerships and clinical trials. The company does not report significant commercial operations outside the United States.

While its antibody programs may ultimately target global infectious disease markets, current international presence is limited to participation in multinational clinical research and regulatory engagement. There is no verified evidence of substantial overseas subsidiaries, manufacturing sites, or direct international sales operations at this time.

Leadership & Governance

SAB Biotherapeutics is led by a management team with experience in biotechnology, immunology, and biologics manufacturing. The leadership emphasizes platform scalability, scientific rigor, and alignment with public health and government stakeholders as core elements of its strategic vision.

Key executives include:

• Eddie J. Sullivan – Chief Executive Officer and Co-Founder
• Karla Lindquist – Chief Financial Officer
• Samuel Reich – Chief Operating Officer
• Michael Ballantyne – Chief Scientific Officer

The company is governed by a board of directors that includes executives and independent members with backgrounds in life sciences, finance, and public markets, consistent with U.S. public company governance standards.